P2.21 Clinical Responses and Survival in Hispanic Patients vs Non-Hispanic White Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy

6050 Background: Hispanics in the United States have a lower age-adjusted incidence and mortality rate from non-small cell lung cancer compared with non-Hispanic whites. Previous studies have demonstrated the influence of nativity on survival among Hispanic patients but no studies have evaluated the interplay of nativity, clinical factors, social factors, and neighborhood factors on survival among Hispanic patients with non-small cell lung cancer. Methods: All Hispanic patients with non-small cell lung cancer between the years of 1988-2008 were identified in the California Cancer Registry (CCR). Kaplan Meier curves depict survival by nativity status among Hispanics with non-small cell lung cancer. Cox proportional hazard models estimate the hazard of mortality by race with adjustment for individual covariates (age, gender, marital status), clinical factors (histologic grade, surgery, radiation, and chemotherapy), and social and neighborhood factors (neighborhood and ethnic enclave status). Results: A total of 4,062 Hispanic patients with non small cell lung cancer were included. Overall, there was a 7% decreased risk of disease-specific mortality for foreign-born patients as compared with US-born patients (HR 0.93, p=0.08, 95% CI 0.87-1.00) although not-statistically significant. Adjustment for individual patient factors and clinical factors conferred a statistically significant 16% decreased risk of disease-specific mortality compared with US-born patients (HR 0.84, p<0.0001, 95% CI 0.78-0.91). Adjustment for socioeconomic status and neighborhood socioeconomic and ethnic enclave status did not explain the differences in survival (HR 0.84, p <0.001, 95% CI 0.78-0.91). Conclusions: Overall, foreign-born Hispanics with non-small cell lung cancer have a decreased risk of disease-specific mortality compared with US-born Hispanics with non-small cell lung cancer but social factors do not explain this survival advantage. Further investigation is needed to understand the drivers of the survival advantage outcomes in foreign-born populations.

Download Full-text

O-152 Immunotherapy with gene-modified allogenic cells successfully induced CD8 T cell and clinical responses in patients with advanced non-small cell lung cancer (NSCLC)

Lung Cancer ◽

10.1016/s0169-5002(03)91810-1 ◽

2003 ◽

Vol 41 ◽

pp. S46-S47

Author(s):

Luis E. Raez ◽

Peter A. Cassileth ◽

James Schlesselman ◽

Swaminathan Padmanabhan ◽

Eva Fisher ◽

...

Keyword(s):

Lung Cancer ◽

T Cell ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cd8 T Cell ◽

Small Cell ◽

Small Cell Lung ◽

Clinical Responses

Download Full-text

ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdx380.038 ◽

2017 ◽

Vol 28 ◽

pp. v476

Author(s):

A. Mc Leer ◽

M. Duruisseaux ◽

J. Pinsolle ◽

S. Dubourg ◽

J. Mondet ◽

...

Keyword(s):

Lung Cancer ◽

Next Generation Sequencing ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Next Generation ◽

Small Cell Lung ◽

Clinical Responses ◽

Alk Positive ◽

Generation Sequencing

Download Full-text

Persistent racial/ethnic associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.

10.1101/2021.11.26.21266821 ◽

2021 ◽

Author(s):

Marcus A Florez ◽

Jan O Kemnade ◽

Nan Chen ◽

Wendy W Du ◽

Anita L Sabichi ◽

...

Keyword(s):

Lung Cancer ◽

Head And Neck ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Small Cell ◽

Equal Access ◽

Small Cell Lung ◽

Hispanic Patients ◽

Hispanic White ◽

White Patients

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of both lung cancer and head and neck squamous cell carcinoma demonstrating clear benefit over traditional chemotherapy alone in the metastatic setting. While the overwhelming majority of ICI trial participants have been White patients, results of these trials have been broadly applied to patients of all ethnic/racial backgrounds. It has, therefore, not been well defined if response to ICIs differs between ethnic/racial populations or socio-economic groups. We reviewed response to ICI of 208 patients with diagnoses of lung or head and neck cancers treated with ICI between 2015 and 2020 at one of three clinical pavilions associated with the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, TX. Two of these pavilions (Harris Health System and the Michael E. DeBakey Veterans Affairs Medical Center) serve large minority patient populations and provide equal access of care to patients regardless of means. Of the 208 patients, 175 had a diagnosis of lung cancer [non-small cell lung carcinoma (NSCLC) or small cell lung cancer (SCLC)] and 33 had a diagnosis of head and neck squamous cell carcinoma (HNSCC); 38% self-identified as Black, 45% as non-Hispanic White, and 18% as Hispanic. The objective response rate (ORR) was similar for lung cancer (31.4%) and HNSCC patients (27.3%) (p=0.894). Statistically, the ORR for Hispanic and Black patients did not differ compared to non-Hispanic White patients (H 23.7%, B 28.6%, W 35.5%; H vs. W p=0.189; B vs. W p=0.338). When considering patients treated with ICI monotherapy, the ORR for Hispanic patients dropped to 13.3% and was significantly lower than the ORR of the non-Hispanic White patients while the ORR of Black and non-Hispanic White patients remained about the same (B 29.3% and W 34.6%, H vs. W p=0.0285; B vs. W p=0.5131). Immune related adverse events (irAEs) were the lowest in the Hispanic population occurring in only 30% of patients compared to 50% of patients exhibiting irAEs in the Black and non-Hispanic white cohorts. ICIs demonstrate comparable anti-tumor effects in lung cancer (NSCLC + SCLC) and HNSCC during routine clinical practice regardless of race or ethnicity. The significantly lower ORR observed in our cohort for Hispanic patients, particularly when used as monotherapy, is an unexpected finding and will require additional study to identify potential biological and non-biological confounders which could contribute to reduced ICI effectiveness in this patient population.

Download Full-text

Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples

Diagnostics ◽

10.3390/diagnostics9010013 ◽

2019 ◽

Vol 9 (1) ◽

pp. 13

Author(s):

Odharnaith O’Brien ◽

Mark Wright ◽

Cathal O’Brien ◽

Orla Geoghegan ◽

Niamh Leonard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Diagnostic Testing ◽

Small Cell ◽

Small Cell Lung ◽

Formalin Fixed Paraffin ◽

Formalin Fixed Paraffin Embedded ◽

Clinical Responses ◽

Cost Efficient

MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis. Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14 skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution in NSCLC.

Download Full-text